INmune Bio adds two directors, Duane Clark and James Sapirstein, to its board
INmune Bio's board increased its size to seven directors and appointed R. Duane Clark II and James Sapirstein as independent directors on September 8, 2026, with both also joining the Nominating and Corporate Governance Committee. The company says the appointments add rare-disease commercialization and business-development experience as it prepares its Ebstrocel candidate for potential commercialization.
Key points
- Board set at seven directors; Clark and Sapirstein appointed on September 8, 2026, serving until the next annual election
- Each director to receive an option to purchase 100,000 shares of common stock, vesting in 36 equal monthly installments
- Each director to receive an annual cash retainer of $50,000, paid quarterly in arrears
- Clark is General Manager, U.S. Rare Diseases at Sanofi; Sapirstein is CEO of Cocrystal Pharma, Inc. (Nasdaq: COCP)
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 14, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.